| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | 6.5% | 5.9% |
| ROCE | 10.2% |
| Latest | F'cast | |
|---|---|---|
| P/E | 29.3 | 35.7 |
| PEG | 0.9 | 2.1 |
| Pr/Revenue | 0.7 | 0.8 |
| Pr/Book | 0.7 |
| Latest | F'cast | |
|---|---|---|
| Revenue | 10.0% | -100.0% |
| PBT | 30.8% | -100.0% |
| EPS | 30.9% | 17.8% |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Mar-22 | 82.19 | 1.39 | (1.01)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Mar-23 | 85.31 | 5.10 | 1.49p | 64.8 | n/a | n/a | n/a | 0.0% |
| 31-Mar-24 | 89.42 | 2.97 | 1.55p | 55.2 | 13.8 | +4% | n/a | 0.0% |
| 31-Mar-25 | 79.60 | 4.46 | 2.49p | 21.5 | 0.4 | +61% | n/a | 0.0% |
| 31-Mar-26 | 87.53 | 5.83 | 3.26p | 29.3 | 0.9 | +31% | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| ECOVAXXIN® MS EU marketing authorisation granted | 22-Dec-2025 | 07:00 | RNS |
| Traded | Action | Notifier | Price | Amount | Value |
|---|---|---|---|---|---|
| 16-Jul-26 | Buy | David Hallas | 89.50p | 22,346 | £19,999.67 |
| Currency | UK Pounds |
| Share Price | 100.00p |
| Change Today | 3.00p |
| % Change | 3.09 % |
| 52 Week High | 114.00p |
| 52 Week Low | 73.00p |
| Volume | 335,387 |
| Shares Issued | 67.76m |
| Market Cap | £67.76m |
| Beta | 0.01 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Latest | Previous | |
|---|---|---|
| Final | Final | |
| Ex-Div | 23-Sep-21 | 26-Sep-19 |
| Paid | 22-Oct-21 | 16-Oct-19 |
| Amount | 1.00p | 7.04p |
| Time | Volume / Share Price |
| 16:42 | 20,000 @ 98.50p |
| 16:36 | 25,000 @ 99.89p |
| 16:33 | 15,000 @ 101.00p |
| 16:32 | 25,000 @ 101.00p |
| 17:06 | 7,000 @ 100.00p |
| CFO | Christopher Wilks |
| CEO | David Hallas |
You are here: research